Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Zimmer Holdings Inc. (ZMH), Avalanche Biotechnologies Inc (AAVL), Wright Medical Group Inc (WMGI): Ghost Tree Capital’s Top Biotech Stocks

Page 1 of 2

David Kim and Ken Greenberg’s Ghost Tree Capital has filed its most recent 13F with the SEC recently, and we poured through it to analyze the fund’s newest picks and top plays, the latter of which we’ll discuss in this feature. It was an active quarter for the fund, which added 33 new positions to its portfolio, while axing 44 previously held ones. All told, the value of the fund, which is 100% invested in the healthcare sector, increased to $208.40 million at the end of 2014, up from $184.24 million at the end of the third quarter.

Ghost Tree Capital

New York-based Ghost Tree Capital was founded in 2013 by Kim and Greenberg, who previously worked together at Diamondback Capital. Prior to that, Kim, the CIO and principal owner of Ghost Tree and a graduate of The Johns Hopkins University School of Medicine, worked at Citadel Investment. Greenberg, currently a senior analyst, was previously a principal at MPM Capital, and before that, an associate at McKinsey & Company. Greenberg graduated from the University of Pennsylvania – The Wharton School with a MBA in General Management & Healthcare. Ghost Tree maintains a highly diversified portfolio, with no single holding accounting for more than 5.65% of the fund’s equity portfolio value at the end of 2014.

The top biotech holding of Ghost Tree heading into 2015 was Zimmer Holdings Inc. (NYSE:ZMH), in which the fund held an 86,200 share stake. That was a 73% increase from the previous quarter, when it held 50,000 shares. Since the fund opened a position in the fourth quarter of 2013, Zimmer Holdings has enjoyed a strong run, up over 30%. The company is involved in the manufacture of various medical devices, including spinal and trauma devices, and dental implants. The $20.49 billion market cap company operates in more than 25 countries around the world, and sells its products in more than 100.

Zimmer is still in the process of merging with Biomet, a private Indiana medical devices manufacturer, for $13.35 billion. That deal, which was announced in April, is still awaiting regulatory approval from the European Commission and the Japan Fair Trade Commission. In its most recent quarterly results, Zimmer Holdings announced net sales of $1.22 billion, down 1.4% year-over-year, and adjusted earnings of $1.71, a 3% increase. Zimmer Holdings goes ex-dividend on March 4, with stockholders as of March 6 being paid the $0.22 dividend on April 24.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!